Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) Price Target Raised to $21.00

Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP) had its price objective increased by HC Wainwright from $8.00 to $21.00 in a research report sent to investors on Tuesday, MarketBeat reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Neuphoria Therapeutics Inc. – Common Stock’s Q2 2025 earnings at ($2.01) EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($1.26) EPS, FY2025 earnings at ($1.56) EPS, Q1 2026 earnings at ($0.55) EPS, Q2 2026 earnings at ($0.61) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($1.85) EPS, FY2027 earnings at ($1.21) EPS and FY2028 earnings at ($1.36) EPS.

Neuphoria Therapeutics Inc. – Common Stock Trading Down 2.1 %

NEUP stock opened at $5.04 on Tuesday. Neuphoria Therapeutics Inc. – Common Stock has a 1-year low of $2.12 and a 1-year high of $16.08.

Neuphoria Therapeutics Inc. – Common Stock Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.